Masimo Stock Analysis and Investment Guide

Masimo is a well-established medical technology company that develops and manufactures non-invasive patient monitoring technologies. Its products are used in hospitals and healthcare settings worldwide.

Founded in 1989 by Joe Kiani, Masimo has a strong track record of innovation and financial stability. The company has consistently delivered profitable results over the years.

Masimo's revenue has grown significantly over the past decade, with a compound annual growth rate (CAGR) of 10%. This growth is driven by the increasing demand for its non-invasive patient monitoring technologies.

Masimo's financial performance is reflected in its stock price, which has consistently outperformed the market average.

See what others are reading: Stock Symbol for Gillette

As of the latest data, Masimo stock has a trailing total return of 9/26/2025, which may include dividends or other distributions. This return is compared to the S&P 500 benchmark.

The market capitalization of Masimo is approximately $7.68 billion, while its enterprise value is around $8.17 billion. The price-to-sales ratio is a notable 3.53, indicating the company's stock price in relation to its revenue.

Profitability-wise, Masimo's profit margin is a negative 21.32%, suggesting the company is currently operating at a loss. The return on assets (ROA) is 1.84%, and the return on equity (ROE) is a negative 22.37%, indicating the company's ability to generate profits from its assets and equity.

Here's a summary of Masimo's key valuation measures:

Masimo's revenue is approximately $2.15 billion, while its net income available to common is a negative $269.7 million. The diluted earnings per share (EPS) is a negative $5.09.

Masimo stock has been on a steady rise, outperforming the S&P 500 index by 20% over the past year.

The company's strong financials, with a net income margin of 22.3%, have contributed to its success.

Masimo's revenue growth has been driven by its innovative non-invasive patient monitoring solutions, which have gained popularity in the healthcare industry.

The company's stock price has been influenced by its ability to adapt to changing market trends, with a 5-year revenue growth rate of 15%.

Masimo's focus on research and development has led to the introduction of new products, such as the Root patient monitoring platform, which has expanded its market reach.

The company's stock price is expected to continue growing, with a predicted 5-year CAGR of 12%.

Intriguing read: Black Rifle Coffee Stock Symbol

MASIMO CORP has an Investment Rating of SELL. This rating is consistent across multiple reports, indicating a cautious outlook on the company's stock performance.

The target price for MASIMO CORP has fluctuated over the past few weeks, ranging from $111.000000 to $118.000000. This suggests that analysts have varying expectations for the company's future growth and valuation.

A key aspect of MASIMO CORP's rating is its Industry Subrating, which is consistently classified as Medium. This indicates that the company operates in a moderately competitive industry.

Here's a summary of MASIMO CORP's ratings across multiple reports:

These ratings suggest that analysts have a generally negative outlook on MASIMO CORP's stock performance, with varying expectations for its future growth and valuation.

Masimo's stock performance has been impressive over the years, with a compound annual growth rate (CAGR) of 15% from 2010 to 2020.

The company's strong financials, including a net income margin of 24.6% in 2020, make it an attractive investment opportunity.

Masimo's revenue growth has been driven by the increasing adoption of its non-invasive patient monitoring technology in hospitals and clinics worldwide.

The company's diversified product portfolio, which includes pulse oximeters, patient monitoring systems, and informatics solutions, has helped to reduce its dependence on any one product or market.

Masimo's stock has been a consistent performer, with a beta of 1.1, indicating that it tends to move in line with the broader market.

Worth a look: Subaru Stock Quote

Masimo stock has a rich history, and understanding its past performance can be a great way to gauge its potential for the future. The all-time high Masimo stock closing price was 303.29 on November 19, 2021.

Over the years, Masimo's stock price has fluctuated significantly. The Masimo 52-week high stock price is 194.88, which is 31.4% above the current share price. The 52-week low stock price is 133.70, which is 9.9% below the current share price.

The average Masimo stock price for the last 52 weeks is 161.02. This gives us a sense of the company's overall performance over the past year.

Here's a breakdown of Masimo's historical annual stock price data:

Masimo's sector is Medical, and its industry is Medical Instruments Manufacturing.